Amgen Reports a Phase 3 Win with Sjögren’s Drug Candidate

Amgen's Horizon buyout delivers Sjögren's disease win

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

Amgen’s autoimmune drug succeeds in late-stage trial

Sept 22 (Reuters) - Amgen said on Tuesday its experimental drug to treat an autoimmune disease that ​attacks the body's moisture-producing ‌glands met the main goal of reducing disease activity in a late-stage trial. Here are some details: • The drug d...

Amgen reports Phase 3 dazodalibep Sjögren's win

OASIZ 301 met its systemic disease measure, but Amgen did not disclose the treatment gap; a second Phase 3 study is due to finish this year.

Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Amgen (AMGN) Stock Surges 4% on Breakthrough Sjögren's Disease Trial Results

Key Highlights Shares of Amgen rose approximately 4% during premarket hours Tuesday following encouraging Phase 3 data for dazodalibep in treating Sjögren’s disease The OASIZ 301 clinical trial achieved its primary goal, demonstrating statistically significant improvements in systemic disease severity at the 48-week mark Positive changes in patient outcomes emerged as soon as Week 4 and remained consistent throughout the complete 48-week trial …